Yield10 Story

Yield10 Bioscience reported the previous year's revenue of 744 K. Net Loss for the year was (14.41 M) with loss before overhead, payroll, taxes, and interest of (4.04 M).

	2015	2020	2021 (projected)
Receivables	388 K	215.05 K	220.71 K
Inventories	379 K	435.85 K	447.32 K

Margins Breakdown

Yield10 profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Yield10 Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Yield10 Bioscience profit margins.

	Operating Margin	7.62
	EBITDA Margin	10.36
	Gross Margin	37.45
	Profit Margin	7.67

Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The latest value of Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is -10,157,103. Yield10 Bioscience Net Income Per Employee is decreasing over the last 8 years. Furthermore, Yield10 Bioscience Revenue Per Employee is decreasing over the last 8 years. Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. Yield10 Bioscience Net Income Per Employee is decreasing over the last 8 years. Furthermore, Yield10 Bioscience Revenue Per Employee is decreasing over the last 8 years.

Will Yield10 Bioscience latest rise continue?

Yield10 Bioscience latest mean deviation surges over 6.86. Yield10 Bioscience is displaying above-average volatility over the selected time horizon. Investors should scrutinize Yield10 Bioscience independently to ensure intended market timing strategies are aligned with expectations about Yield10 Bioscience volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Yield10 Bioscience's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Yield10 Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Conclusion on Yield10 Bioscience

Whereas few other entities within the agricultural inputs industry are still a little expensive, even after the recent corrections, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. To summarize, as of the 13th of March 2021, our analysis shows that Yield10 Bioscience barely shadows the market. The company is undervalued and projects high chance of distress for the next 2 years. However, our latest 30 days buy-sell recommendation on the company is Strong Sell.